ljc 10627 has been researched along with Koch's Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Bhaskar, A; Chaturvedi, S; Dwivedi, VP; Ghoshal, A; Kumari, A; Mukhopadhyay, S; Pahuja, I; Shaji, A; Verma, A | 1 |
| Ammerman, NC; Dooley, KE; Dorman, SE; Kaushik, A; Lamichhane, G; Nuermberger, EL; Story-Roller, E; Tasneen, R | 1 |
1 review(s) available for ljc 10627 and Koch's Disease
| Article | Year |
|---|---|
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
2 other study(ies) available for ljc 10627 and Koch's Disease
| Article | Year |
|---|---|
Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; CD8-Positive T-Lymphocytes; COVID-19; Disease Models, Animal; Immunity; Immunologic Factors; Mice; Mycobacterium tuberculosis; Tuberculosis | 2023 |
In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Female; Mice, Inbred BALB C; Microbial Viability; Mycobacterium tuberculosis; Rifampin; Thienamycins; Treatment Outcome; Tuberculosis | 2017 |